A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients

BACKGROUND: Neo-adjuvant chemoradiotherapy followed by surgery is the standard treatment with curative intent for oesophageal cancer patients, with 5-year overall survival rates up to 50 %. However, patients’ quality of life is severely compromised by oesophagectomy, and eventually many patients die...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Larue, Ruben T. H. M., Van De Voorde, Lien, Berbée, Maaike, van Elmpt, Wouter J. C., Dubois, Ludwig J., Panth, Kranthi M., Peeters, Sarah G. J. A., Claessens, Ann, Schreurs, Wendy M. J., Nap, Marius, Warmerdam, Fabiënne A. R. M., Erdkamp, Frans L. G., Sosef, Meindert N., Lambin, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4989456/
https://ncbi.nlm.nih.gov/pubmed/27535748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2709-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados